Trial Profile
Randomized, double-blind, placebo-controlled, sequential-group, ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of IMA-638 administered subcutaneously and intravenously to subjects with asthma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Dec 2015
Price :
$35
*
At a glance
- Drugs Anrukinzumab (Primary) ; Anrukinzumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- 24 Jul 2007 Status changed from recuiting to completed.
- 07 Oct 2006 New trial record.